NASDAQ:FBLG

Fibrobiologics Stock News

Healthcare > Biotechnology

Buy FBLG

*Your capital is at risk

$1.07

+0.0200 (+1.90%)

At Close: Jun 03, 2026

FibroBiologics to Present at JonesTrading Healthcare Summit 2024

09:31am, Monday, 15'th Jul 2024

HOUSTON, July 15, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the d

FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technology

09:31am, Tuesday, 25'th Jun 2024

HOUSTON, June 25, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the deve

FibroBiologics Set to Join Russell 2000® Index

09:31am, Thursday, 13'th Jun 2024

HOUSTON, June 13, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the dev

FibroBiologics to Present at Extracellular Matrix Pharmacology Congress 2024

09:31am, Thursday, 06'th Jun 2024

HOUSTON, June 06, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the dev

FibroBiologics Announces 2024 Annual Meeting of Stockholders

04:30pm, Wednesday, 15'th May 2024

HOUSTON, May 15, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the de

FibroBiologics Files 2024 First Quarter Report

05:24pm, Tuesday, 14'th May 2024

HOUSTON, May 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of

FibroBiologics to Present at the BIO International Convention 2024

09:31am, Tuesday, 07'th May 2024

HOUSTON, May 07, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the de

FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office

09:31am, Thursday, 11'th Apr 2024

HOUSTON, April 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the

FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA

09:31am, Thursday, 04'th Apr 2024

HOUSTON, April 04, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of

FibroBiologics to Present Preclinical and Clinical Data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum

09:31am, Tuesday, 20'th Feb 2024

HOUSTON , Feb. 20, 2024 /PRNewswire/ -- FibroBiologics (Nasdaq: FBLG) ("FibroBiologics") is a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by